YUEER GENE
Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.
YUEER GENE
Industry:
Big Data Genetics Health Care Medical
Founded:
2017-01-01
Address:
Yangpu, Hainan, China
Country:
China
Website Url:
http://www.carriergene.com
Total Employee:
11+
Status:
Active
Contact:
400-999-8036
Email Addresses:
[email protected]
Total Funding:
50 M USD
Technology used in webpage:
China Telecom Chinese Server Location
Similar Organizations
Encoded Therapeutics
Encoded Therapeutics is a Harnessing the regulatory genome to create next-generation molecular therapies.
Genome Medical
Genome Medical is a telegenomics technology and services company allowing access to genomic-based medicine.
HealthVerity
HealthVerity powers the discovery, licensing, and linkage of traditional and emerging healthcare data.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Navina
Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.
Pera Labs
Pera Labs develops digiceuticals and AI-powered solutions for fertility.
TowerView Health
TowerView Health develops an application for patients to manage medications.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Investors List
Pappas Capital
Pappas Capital investment in Series B - Yueer Gene
Haoreng Capital
Haoreng Capital investment in Series B - Yueer Gene
Pan-Lin Capital
Pan-Lin Capital investment in Series B - Yueer Gene
Sequoia Capital China
Sequoia Capital China investment in Series B - Yueer Gene
Boyuan Capital
Boyuan Capital investment in Series B - Yueer Gene
AstraZeneca
AstraZeneca investment in Series B - Yueer Gene
CR-CP Life Science Fund
CR-CP Life Science Fund investment in Series B - Yueer Gene
Yonghua Capital
Yonghua Capital investment in Series B - Yueer Gene
Official Site Inspections
http://www.carriergene.com
- Host name: 106.14.15.24
- IP address: 106.14.15.24
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Yueer Gene"
阅尔基因
Reproductive Health 生殖健康. 专门针对不孕不育、反复流产、新生儿缺陷等生殖健康问题设计研发基因检测panelSee details»
CarrierGene — iGene Laboratory
CarrierGene Focus: is a pan-ethnic screening panel of 119 genes known to be curated to South East Asia population carrier frequencies. As recommeded by ACMG, all pregnant individuals …See details»
关于阅尔-公司简介-阅尔基因 - carriergene.com
阅尔基因是一家技术创新驱动的全球基因组学公司，拥有多项革命性的分子诊断专利技术，可将所有NGS平台的测序成本降低50倍以上，并将qPCR，Sanger和纳米孔测序的灵敏度提高100倍以上。See details»
关于阅尔-核心成员-阅尔基因 - carriergene.com
张宇 联合创始人 创新中心副总裁. 莱斯大学生物工程学终身教授，拥有20多项专利发明； 超过10项专利已授权给5家行业领先的基因组学和分子诊断公司；See details»
NuProbe Appointed Yingshuang Chai as CEO, and Established …
Jan 6, 2020 The merger with CarrierGene will result in more products that benefit patients in a wider range of disease indications, ” said David R. Walt, Ph.D., member of the National …See details»
CarrierGene Biotech Co., Ltd. - Drug pipelines, Patents, Clinical ...
Explore CarrierGene Biotech Co., Ltd. with its drug pipeline, therapeutic area, technology platform, .See details»
CarrierGene Biotech (Suzhou) Co., Ltd Asset Profile | Preqin
Established in 2017 and based in Suzhou, China, CarrierGene Biotech (Suzhou) Co., Ltd is a gene detection company that focuses on genetic screening and diagnosis through genetic …See details»
CarrierGene Biotech - Products, Competitors, Financials, …
Yingshuang Chai, co-founder and former CEO of CarrierGene, will be CEO and Chairman of the merged NuProbe Board. BioTrack Capital of Shanghai made an investment of unspecified size …See details»
Carrier Gene Company Profile 2024: Valuation, Investors
Carrier Gene General Information Description. Developer of genomics and molecular diagnostics tests intended to improve the sensitivity of sequencing mutations. The company specializes in …See details»
Yueer Gene - Crunchbase Company Profile & Funding
Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the …See details»
Partnerships — iGene Laboratory
CarrierGene; HPV HR14; STI-7; Pre-Natal. iGene® NIPT; SingGene NIPT; CarrierGene; STI-7; Fetal DNA Chip (version 2.0) Fetal Seq (version 1.0) Fetal Exome; ... For Contract Research …See details»
CarrierGene Biotech Co., Ltd. (阅尔基因技术（苏州）有限公司)
了解CarrierGene Biotech Co., Ltd. (阅尔基因技术（苏州）有限公司)公司的药物管线，治疗领域，技术平台，以及它的15篇新闻。See details»
NuProbe Global and CarrierGene Biotech Co. Ltd ... - Business Wire
Jan 8, 2020 About CarrierGene Biotech Co. Ltd. Founded in 2016, CarrierGene was co-founded by former senior employees from first-line companies in the genomics industry such as …See details»
NuProbe Global, CarrierGene Biotech Complete Merger, Partner …
Jan 6, 2020 Former CarrierGene CEO and Cofounder Yingshuang Chai will serve as CEO of the new company. R&D will take place in Houston and Shanghai. NuProbe spun out of Harvard's …See details»
SingGene NIPT — iGene Laboratory
SingGene NIPT utilizes cell-free DNA (cfDNA) to directly assess fetal genetic information, resulting in a significant increase (see comparison below) in the detection of affected …See details»
专利技术屡屡授权转让给国际测序巨头，阅尔基因是一家怎样的企 …
另一方面，阅尔基因（CarrierGene）团队也密切关注肿瘤分子诊断市场，持续研发创新的平台型技术，旨在推出差异化的肿瘤分子诊断产品。 阅尔基因（CarrierGene）于2017年通过美 …See details»
阅尔基因 | 项目信息-36氪
阅尔基因是一家技术创新驱动的全球基因组学公司，拥有多项革命性的分子诊断专利技术，可将所有NGS平台的测序成本降低50倍以上，并将qPCR，Sanger和纳米孔测序的灵敏度提高100倍 …See details»
阅尔基因学院成立并成功举办首届不孕不育遗传培训班
NUPROBE NEWS. 2021年1月9日，由阅尔基因（NuProbe）发起、国内外医疗健康和科学研究领域资深专家共同参与的阅尔基因学院（NuProbe College）于在上海正式成立，并于1月9日 …See details»
HPV HR14 — iGene Laboratory
Every year, over 600,000 women are diagnosed with cervical cancer, primarily linked to human papillomavirus (HPV) 1.In response, the World Health Organization (WHO) has advocated for …See details»
精阅®男性不育基因检测panel（仅供科研） - carriergene.com
结果解读. 患者 cftr 基因 4 号和 18 号外显子存在杂合突变，其致病性为疑似致病;先天性双侧输精管缺如和囊性 纤维化的遗传方式都是常染色体隐性遗传; 若其配偶为相同突变携带者，则其子 …See details»